SlideShare a Scribd company logo
1 of 43
Download to read offline
Merck KGaA
Darmstadt, Germany
Dr. Leo Ohrem
September 6, 2018
How can excipients support you?
The life science business of
Merck KGaA, Darmstadt, Germany
operates as MilliporeSigma
in the U.S. and Canada.
Webinar API stability in solid dose - How can excipients support you?2
In this webinar, you will learn about:
What is the impact of poor API stability?
What factors affect API stability?
How can excipients help?
3
2
1
Case studies
Key takeaways
4
5Webinar API stability in solid dose - How can excipients support you?3
The need of good API stability
API stability has to be proven in registration
Acceptance by authorities
Short shelf life
Worse economics
Burden on supply chain
Difficult storage conditions
Accuracy of patient dosage
Reduced strength over shelf life
1
2
3
4
Webinar API stability in solid dose - How can excipients support you?4
Reasons for lack of API stability
pH Sensitivity
Oxidation
Heat/
Temperature
Light
Sensitivity
Moisture
Biological
threats
Webinar API stability in solid dose - How can excipients support you?5
Excipients
typically thought
of as inert
What effect do excipients have?
Webinar API stability in solid dose - How can excipients support you?6
Fillers
Lubricants, flow enhancers,
disintegrants, binders, coatings,
pigments
No function
wanted
Physical
action
pH adjustment, preservatives,
antioxidants, scavengers, taste
modifiers
Chemical
activity
Wanted interaction with API:
Excipients to alter solubility,
recrystallisation, permeability, in situ
salt formation
complexation
Bioavailability
Factors affecting API stability
How to use traditional approaches to limit stability issues?
Direct
interaction /
reactivity
Granulation process
Compression force
Oxidation
Moisture content
Impurities
Hygroscopicity
Webinar API stability in solid dose - How can excipients support you?7
Examples:
 Lactose?
 Mg-Stearate?
 Ca-Phosphate?
Direct interaction
Are excipients inert?
Excipients can interact with APIs – Strategy: leave out when possible.
Webinar API stability in solid dose - How can excipients support you?9
Substance Water content
Starch < 15 %
MCC < 7 %
Isomalt < 7 %
Excipient System A < 5.75 %
Excipient System B < 3.5 %
Excipient System C < 3 %
Lactose monohydrate < 1 %
DC-Mannitol < 0.3 %
Excipients systems A-C are ready-to-use
systems of the following composition:
 A: lactose monohydrate, povidone,
crospovidone
 B: lactose monohydrate, cellulose
 C: lactose monohydrate, maize starch
Moisture Content
Water content of excipients matters
Mannitol is the best choice to use with moisture sensitive APIs
Webinar API stability in solid dose - How can excipients support you?11
Rowe, R. C., P. J. Sheskey, et al., Eds. (2009). Handbook of Pharmaceutical Excipients. 6th Edition. London,
Washington DC, Pharmaceutical Press and American Pharmacists Association or manufacturer’s information.
Hygroscopicity
Comparison of filler excipients
Least hygroscopicity for Mannitol
Even sorbitol may work well, if humidity can be controlled
Webinar API stability in solid dose - How can excipients support you?12
Keep it simple!
What you leave out, you do not need to worry about
Wu Y, Levons J, Narang AS, Raghavan K, Rao VM. Reactive Impurities in Excipients: Profiling, Identification and Mitigation
of Drug–Excipient Incompatibility. AAPS PharmSciTech. 2011;12(4):1248-1263. doi:10.1208/s12249-011-9677-z.
Impurities
Excipients and their impurities
Webinar API stability in solid dose - How can excipients support you?14
• MCC Water, glucose (reducing sugar), hydrogen bonding ( retardation),
aldehydes, free radicals/peroxides
• Glucose, Lactose Water, aldehydes, formic acid, reducing sugar
• Starch Water, reducing sugar, aldehydes
• HPMC Water, reducing sugar, retardation, aldehydes
• PEG, Tween Aldehydes, peroxides
• Povidone Peroxides, aldehydes, retardation
• Crospovidone Peroxides, aldehydes
How to minimize:
Commercial standard according to pharmacopoeia limits for polyols (mannitol, sorbitol)
Ph. Eur.  max. 0.10 %
USP  max. 0.30 %
Impurities
Reducing sugars are cause for instability and browning (Maillard reaction)
15 Webinar API stability in solid dose - How can excipients support you?
Is this limit sufficient for API stability?
Mannitol A with API, tested after storage (60°C, 7 days),
The content of the target impurity is 1.91%
Mannitol A & API, tested after blending
Mannitol B & API, tested after blending
Mannitol B with API, tested after storage (60°C, 7 days),
The content of the target impurity is 0.57%
Unwanted related substance from the reaction of API
impurity (amine) and the reducing sugars in the Mannitol.
min
signal
Impurities
Reaction of API impurity with reducing sugars in mannitol
Webinar API stability in solid dose - How can excipients support you?16
Impurity levels can be different between suppliers of the same type of excipient
Impurities
Webinar API stability in solid dose - How can excipients support you?17
DC Formulation with
Mannitol A
• Unwanted degradation
product of API: 6.5%
DC Formulation with Mannitol B
• Unwanted API degradation
product of API: 1.5%
• Many fewer types of
impurities identified
The choice of excipient and the respective level of impurities are critical factors
influencing API stability
Formulation of mannitols from different suppliers using direct compression
Impurities
Example: Reducing sugars in Parteck® M excipient batch to batch
Webinar API stability in solid dose - How can excipients support you?18
Typical values of an impurity are never the same as the specification limits.
Peroxides in ready-to-use ODT systems
Composition of RTU ODT excipient systems:
 A: Mannitol, croscarmellose sodium
 B: Lactose, starch
 C: Mannitol, crospovidone, povidone, polyvinyl acetate
 D: Mannitol, xylitol, MCC, crospovidone, calcium
dihydrogen phosphate dihydrate
 E: Mannitol, xylitol, MCC, crospovidone, Mg Al Silicate
 F: Mannitol, fructose, MCC, silicon dioxide,
crospovidone
 G: Mannitol, starch
Oxidation
Webinar API stability in solid dose - How can excipients support you?20
Look for low levels of peroxides to improve API stability
Compression Force
How can compression force affect API stability?
Temperature rise Shear force breaks up
large molecules
Shear force breaks up
coated API particles
Webinar API stability in solid dose - How can excipients support you?22
Compression Force
Effect on coated API particles
23 Webinar API stability in solid dose - How can excipients support you?
API
F
API
API
F
API Stability
Sustained
release
Taste
Masking
Compression Force
Webinar API stability in solid dose - How can excipients support you?24
Old formulation
Filler/binder Mannitol C
Compression
force
18 kN
Tablet hardness 40 N
DC Case Study: Enhanced stability of Vit. D3 by reduced compression force
Compression Force
DC Case Study: Enhanced stability of Vit. D3 by reduced compression force
Webinar API stability in solid dose - How can excipients support you?25
Old formulation New formulation
Filler/binder Mannitol C Mannitol B
Compression
force
18 kN 2 kN
Tablet hardness 40 N 55 N
Using the right excipient can help maximize hardness with minimizing
compression force
Compression Force
Evaluation of different excipients for direct compression
Webinar API stability in solid dose - How can excipients support you?26
Sorbitol and spray-dried mannitol deliver superior compressibility
Compression Force
Particle Engineering creates compressibility
Webinar API stability in solid dose - How can excipients support you?27
Large surface areas show great compressibility
What is most suitable for sensitive APIs:
Wet granulation?
Roller compaction?
Webinar API stability in solid dose - How can excipients support you?29
Direct
compression!
Granulation Process
Limitations in direct compression
Webinar API stability in solid dose - How can excipients support you?30
1
2
3
Content Uniformity
Compressibility
Flow
Granulation Process
Statistical mixture vs ordered mixture
Webinar API stability in solid dose - How can excipients support you?31
Common
knowledge:
Homogenous
mixtures only
possible for
similar particle
sizes
Granulation Process
Statistical mixture vs ordered mixture
Webinar API stability in solid dose - How can excipients support you?32
Spray-dried Mannitol A
+ 1% Ascorbic Acid < 10µm
Spray-dried Mannitol B
+ 1% Ascorbic Acid < 10µm
Granulation Process
Statistical mixture vs ordered mixture
Webinar API stability in solid dose - How can excipients support you?33
Large structured surface enables ordered mixtures by adsorption of the API
Case study 1
Direct compression with low dose actives
Webinar API stability in solid dose - How can excipients support you?35
Avicel is a registered trademark of FMC Corporation, Delaware, USA.
Compritol is a registered trademark of Gattefossé SAS, Saint-Priest, France.
A low dose water-sensitive active should be directly compressed
Webinar API stability in solid dose - How can excipients support you?36
40.000 Tab/h 80.000 Tab/h
Tablet weight 120.1 mg (rel.sd.: 0.6%) 118.8 (rel.sd.: 0.9%)
Hardness 178 N (rel.sd. 4.1%) 173 N (rel.sd: 4.1%)
Disintegration 3'25'' 3'22''
Structured surface enables perfect content uniformity;
good flow leads to constant perfomance
Case study 1
Direct compression with low dose actives
Webinar API stability in solid dose - How can excipients support you?37
Case study 1
How can we explain that?
Highlight traditionally difficult unstable API: Atorvastatin
Atorvastatin is known to be:
 Heat sensitive
 Moisture sensitive
 Oxidation sensitive
 Light sensitive
 Acid sensitive
 Unstable in amorphous form
Case study 2
API Stability
39 Webinar API stability in solid dose - How can excipients support you?
Use Mannitol in direct compression together with alkalizer
Case study 2
How to solve stability issues of Atorvastatin?
40 Webinar API stability in solid dose - How can excipients support you?
 Heat sensitive
 Moisture sensitive
 Oxidation sensitive
 Light sensitive
 Acid sensitive
 Unstable in amorphous form
 Omit wet granulation
 Direct compression
 Low compression force
 Keep out peroxides
 Add alkalizer (Meglumine
Parteck® MgDC Excipient, CaCO3)
API stability in solid dose – How can excipients support you?
Key takeaways
Webinar API stability in solid dose - How can excipients support you?41
Dr. Leo Ohrem
hans-leonhard.ohrem@emdgroup.com
The vibrant M is a trademark of Merck KGaA, Darmstadt, Germany or its affiliates. All other
trademarks are the property of their respective owners. Detailed information on trademarks
is available via publicly accessible resources.
© Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

More Related Content

What's hot

Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs
Merck Life Sciences
 
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) DeliveryThe Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
Merck Life Sciences
 
Facility Intensification and Cost Reduction using an Integrated Buffer Delive...
Facility Intensification and Cost Reduction using an Integrated Buffer Delive...Facility Intensification and Cost Reduction using an Integrated Buffer Delive...
Facility Intensification and Cost Reduction using an Integrated Buffer Delive...
Merck Life Sciences
 
Payload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical TimelinesPayload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical Timelines
Merck Life Sciences
 

What's hot (15)

The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
 
Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs
 
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) DeliveryThe Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
 
Media and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMedia and Process Development for Seed Train Intensification
Media and Process Development for Seed Train Intensification
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
 
Overcoming Challenges in Ophthalmic Formulations through Polymer Selection – ...
Overcoming Challenges in Ophthalmic Formulations through Polymer Selection – ...Overcoming Challenges in Ophthalmic Formulations through Polymer Selection – ...
Overcoming Challenges in Ophthalmic Formulations through Polymer Selection – ...
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
 
Facility Intensification and Cost Reduction using an Integrated Buffer Delive...
Facility Intensification and Cost Reduction using an Integrated Buffer Delive...Facility Intensification and Cost Reduction using an Integrated Buffer Delive...
Facility Intensification and Cost Reduction using an Integrated Buffer Delive...
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
Technology Trends in Bioprocessing Purification
Technology Trends in Bioprocessing PurificationTechnology Trends in Bioprocessing Purification
Technology Trends in Bioprocessing Purification
 
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) deliveryThe Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
 
Addressing Downstream Challenges with Complex Injectables
Addressing Downstream Challenges with Complex InjectablesAddressing Downstream Challenges with Complex Injectables
Addressing Downstream Challenges with Complex Injectables
 
Process Scale Chromatography
Process Scale ChromatographyProcess Scale Chromatography
Process Scale Chromatography
 
Payload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical TimelinesPayload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical Timelines
 

Similar to API Stability in Solid Dose Formulation – the Myth of Inert Excipients

Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...
Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...
Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...
MilliporeSigma
 
Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs
MilliporeSigma
 
AMIT - QbD, a case study
AMIT - QbD, a case studyAMIT - QbD, a case study
AMIT - QbD, a case study
Amit Mukharya
 
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) DeliveryThe Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
MilliporeSigma
 
2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured
2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured
2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured
Uma Kakde
 
Natural based hair conditioning
Natural based hair conditioningNatural based hair conditioning
Natural based hair conditioning
Younis I Munshi
 
Evaluation of Decontamination Solutions
Evaluation of Decontamination SolutionsEvaluation of Decontamination Solutions
Evaluation of Decontamination Solutions
DIv CHAS
 

Similar to API Stability in Solid Dose Formulation – the Myth of Inert Excipients (20)

Continuous Manufacturing - Issues and Answers
Continuous Manufacturing - Issues and AnswersContinuous Manufacturing - Issues and Answers
Continuous Manufacturing - Issues and Answers
 
Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...
Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...
Hot melt extrusion with PVA – solubility enhancement, supersaturation perform...
 
PVA for sustained release: theory and practice
PVA for sustained release: theory and practicePVA for sustained release: theory and practice
PVA for sustained release: theory and practice
 
PVA for sustained release: theory and practice
PVA for sustained release: theory and practicePVA for sustained release: theory and practice
PVA for sustained release: theory and practice
 
Solity 3p-applications
Solity 3p-applicationsSolity 3p-applications
Solity 3p-applications
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita Rajput
 
Understanding of Product & Process for Installation of Appropriate Controls (...
Understanding of Product & Process for Installation of Appropriate Controls (...Understanding of Product & Process for Installation of Appropriate Controls (...
Understanding of Product & Process for Installation of Appropriate Controls (...
 
Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs Hot melt extrusion with PVA: A new opportunity for challenging APIs
Hot melt extrusion with PVA: A new opportunity for challenging APIs
 
Catalogo_AGRO_Tank_mix_adjuvants.pdf
Catalogo_AGRO_Tank_mix_adjuvants.pdfCatalogo_AGRO_Tank_mix_adjuvants.pdf
Catalogo_AGRO_Tank_mix_adjuvants.pdf
 
AMIT - QbD, a case study
AMIT - QbD, a case studyAMIT - QbD, a case study
AMIT - QbD, a case study
 
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) deliveryThe Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
 
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) deliveryThe Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) delivery
 
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) DeliveryThe Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery
 
Produktkatalog_2016
Produktkatalog_2016Produktkatalog_2016
Produktkatalog_2016
 
2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured
2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured
2016_BASF_Oleochemical-Brochure_8-5x11_EL-Final Secured
 
Natural based hair conditioning
Natural based hair conditioningNatural based hair conditioning
Natural based hair conditioning
 
Evaluation of Decontamination Solutions
Evaluation of Decontamination SolutionsEvaluation of Decontamination Solutions
Evaluation of Decontamination Solutions
 
Advil vs nano
Advil vs nanoAdvil vs nano
Advil vs nano
 
Training module for nurses for AMSP1.pptx
Training module for nurses for AMSP1.pptxTraining module for nurses for AMSP1.pptx
Training module for nurses for AMSP1.pptx
 
Ppt 2011
Ppt 2011Ppt 2011
Ppt 2011
 

More from MilliporeSigma

Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
MilliporeSigma
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
MilliporeSigma
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
MilliporeSigma
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
MilliporeSigma
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
MilliporeSigma
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
MilliporeSigma
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
MilliporeSigma
 

More from MilliporeSigma (20)

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
 
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 

Recently uploaded

Conjugation, transduction and transformation
Conjugation, transduction and transformationConjugation, transduction and transformation
Conjugation, transduction and transformation
Areesha Ahmad
 
Module for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learningModule for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learning
levieagacer
 
Digital Dentistry.Digital Dentistryvv.pptx
Digital Dentistry.Digital Dentistryvv.pptxDigital Dentistry.Digital Dentistryvv.pptx
Digital Dentistry.Digital Dentistryvv.pptx
MohamedFarag457087
 
biology HL practice questions IB BIOLOGY
biology HL practice questions IB BIOLOGYbiology HL practice questions IB BIOLOGY
biology HL practice questions IB BIOLOGY
1301aanya
 
POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.
Silpa
 
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...
Scintica Instrumentation
 
development of diagnostic enzyme assay to detect leuser virus
development of diagnostic enzyme assay to detect leuser virusdevelopment of diagnostic enzyme assay to detect leuser virus
development of diagnostic enzyme assay to detect leuser virus
NazaninKarimi6
 
Human genetics..........................pptx
Human genetics..........................pptxHuman genetics..........................pptx
Human genetics..........................pptx
Silpa
 

Recently uploaded (20)

Conjugation, transduction and transformation
Conjugation, transduction and transformationConjugation, transduction and transformation
Conjugation, transduction and transformation
 
pumpkin fruit fly, water melon fruit fly, cucumber fruit fly
pumpkin fruit fly, water melon fruit fly, cucumber fruit flypumpkin fruit fly, water melon fruit fly, cucumber fruit fly
pumpkin fruit fly, water melon fruit fly, cucumber fruit fly
 
Module for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learningModule for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learning
 
Exploring Criminology and Criminal Behaviour.pdf
Exploring Criminology and Criminal Behaviour.pdfExploring Criminology and Criminal Behaviour.pdf
Exploring Criminology and Criminal Behaviour.pdf
 
PSYCHOSOCIAL NEEDS. in nursing II sem pptx
PSYCHOSOCIAL NEEDS. in nursing II sem pptxPSYCHOSOCIAL NEEDS. in nursing II sem pptx
PSYCHOSOCIAL NEEDS. in nursing II sem pptx
 
Introduction of DNA analysis in Forensic's .pptx
Introduction of DNA analysis in Forensic's .pptxIntroduction of DNA analysis in Forensic's .pptx
Introduction of DNA analysis in Forensic's .pptx
 
Factory Acceptance Test( FAT).pptx .
Factory Acceptance Test( FAT).pptx       .Factory Acceptance Test( FAT).pptx       .
Factory Acceptance Test( FAT).pptx .
 
Digital Dentistry.Digital Dentistryvv.pptx
Digital Dentistry.Digital Dentistryvv.pptxDigital Dentistry.Digital Dentistryvv.pptx
Digital Dentistry.Digital Dentistryvv.pptx
 
GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)
 
biology HL practice questions IB BIOLOGY
biology HL practice questions IB BIOLOGYbiology HL practice questions IB BIOLOGY
biology HL practice questions IB BIOLOGY
 
POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.
 
An introduction on sequence tagged site mapping
An introduction on sequence tagged site mappingAn introduction on sequence tagged site mapping
An introduction on sequence tagged site mapping
 
GBSN - Microbiology (Unit 3)
GBSN - Microbiology (Unit 3)GBSN - Microbiology (Unit 3)
GBSN - Microbiology (Unit 3)
 
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle ...
 
Zoology 5th semester notes( Sumit_yadav).pdf
Zoology 5th semester notes( Sumit_yadav).pdfZoology 5th semester notes( Sumit_yadav).pdf
Zoology 5th semester notes( Sumit_yadav).pdf
 
development of diagnostic enzyme assay to detect leuser virus
development of diagnostic enzyme assay to detect leuser virusdevelopment of diagnostic enzyme assay to detect leuser virus
development of diagnostic enzyme assay to detect leuser virus
 
GBSN - Microbiology (Unit 2)
GBSN - Microbiology (Unit 2)GBSN - Microbiology (Unit 2)
GBSN - Microbiology (Unit 2)
 
Human genetics..........................pptx
Human genetics..........................pptxHuman genetics..........................pptx
Human genetics..........................pptx
 
Locating and isolating a gene, FISH, GISH, Chromosome walking and jumping, te...
Locating and isolating a gene, FISH, GISH, Chromosome walking and jumping, te...Locating and isolating a gene, FISH, GISH, Chromosome walking and jumping, te...
Locating and isolating a gene, FISH, GISH, Chromosome walking and jumping, te...
 
COMPUTING ANTI-DERIVATIVES (Integration by SUBSTITUTION)
COMPUTING ANTI-DERIVATIVES(Integration by SUBSTITUTION)COMPUTING ANTI-DERIVATIVES(Integration by SUBSTITUTION)
COMPUTING ANTI-DERIVATIVES (Integration by SUBSTITUTION)
 

API Stability in Solid Dose Formulation – the Myth of Inert Excipients

  • 1. Merck KGaA Darmstadt, Germany Dr. Leo Ohrem September 6, 2018 How can excipients support you?
  • 2. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Webinar API stability in solid dose - How can excipients support you?2
  • 3. In this webinar, you will learn about: What is the impact of poor API stability? What factors affect API stability? How can excipients help? 3 2 1 Case studies Key takeaways 4 5Webinar API stability in solid dose - How can excipients support you?3
  • 4. The need of good API stability API stability has to be proven in registration Acceptance by authorities Short shelf life Worse economics Burden on supply chain Difficult storage conditions Accuracy of patient dosage Reduced strength over shelf life 1 2 3 4 Webinar API stability in solid dose - How can excipients support you?4
  • 5. Reasons for lack of API stability pH Sensitivity Oxidation Heat/ Temperature Light Sensitivity Moisture Biological threats Webinar API stability in solid dose - How can excipients support you?5
  • 6. Excipients typically thought of as inert What effect do excipients have? Webinar API stability in solid dose - How can excipients support you?6 Fillers Lubricants, flow enhancers, disintegrants, binders, coatings, pigments No function wanted Physical action pH adjustment, preservatives, antioxidants, scavengers, taste modifiers Chemical activity Wanted interaction with API: Excipients to alter solubility, recrystallisation, permeability, in situ salt formation complexation Bioavailability
  • 7. Factors affecting API stability How to use traditional approaches to limit stability issues? Direct interaction / reactivity Granulation process Compression force Oxidation Moisture content Impurities Hygroscopicity Webinar API stability in solid dose - How can excipients support you?7
  • 8.
  • 9. Examples:  Lactose?  Mg-Stearate?  Ca-Phosphate? Direct interaction Are excipients inert? Excipients can interact with APIs – Strategy: leave out when possible. Webinar API stability in solid dose - How can excipients support you?9
  • 10.
  • 11. Substance Water content Starch < 15 % MCC < 7 % Isomalt < 7 % Excipient System A < 5.75 % Excipient System B < 3.5 % Excipient System C < 3 % Lactose monohydrate < 1 % DC-Mannitol < 0.3 % Excipients systems A-C are ready-to-use systems of the following composition:  A: lactose monohydrate, povidone, crospovidone  B: lactose monohydrate, cellulose  C: lactose monohydrate, maize starch Moisture Content Water content of excipients matters Mannitol is the best choice to use with moisture sensitive APIs Webinar API stability in solid dose - How can excipients support you?11 Rowe, R. C., P. J. Sheskey, et al., Eds. (2009). Handbook of Pharmaceutical Excipients. 6th Edition. London, Washington DC, Pharmaceutical Press and American Pharmacists Association or manufacturer’s information.
  • 12. Hygroscopicity Comparison of filler excipients Least hygroscopicity for Mannitol Even sorbitol may work well, if humidity can be controlled Webinar API stability in solid dose - How can excipients support you?12
  • 13.
  • 14. Keep it simple! What you leave out, you do not need to worry about Wu Y, Levons J, Narang AS, Raghavan K, Rao VM. Reactive Impurities in Excipients: Profiling, Identification and Mitigation of Drug–Excipient Incompatibility. AAPS PharmSciTech. 2011;12(4):1248-1263. doi:10.1208/s12249-011-9677-z. Impurities Excipients and their impurities Webinar API stability in solid dose - How can excipients support you?14 • MCC Water, glucose (reducing sugar), hydrogen bonding ( retardation), aldehydes, free radicals/peroxides • Glucose, Lactose Water, aldehydes, formic acid, reducing sugar • Starch Water, reducing sugar, aldehydes • HPMC Water, reducing sugar, retardation, aldehydes • PEG, Tween Aldehydes, peroxides • Povidone Peroxides, aldehydes, retardation • Crospovidone Peroxides, aldehydes
  • 15. How to minimize: Commercial standard according to pharmacopoeia limits for polyols (mannitol, sorbitol) Ph. Eur.  max. 0.10 % USP  max. 0.30 % Impurities Reducing sugars are cause for instability and browning (Maillard reaction) 15 Webinar API stability in solid dose - How can excipients support you? Is this limit sufficient for API stability?
  • 16. Mannitol A with API, tested after storage (60°C, 7 days), The content of the target impurity is 1.91% Mannitol A & API, tested after blending Mannitol B & API, tested after blending Mannitol B with API, tested after storage (60°C, 7 days), The content of the target impurity is 0.57% Unwanted related substance from the reaction of API impurity (amine) and the reducing sugars in the Mannitol. min signal Impurities Reaction of API impurity with reducing sugars in mannitol Webinar API stability in solid dose - How can excipients support you?16 Impurity levels can be different between suppliers of the same type of excipient
  • 17. Impurities Webinar API stability in solid dose - How can excipients support you?17 DC Formulation with Mannitol A • Unwanted degradation product of API: 6.5% DC Formulation with Mannitol B • Unwanted API degradation product of API: 1.5% • Many fewer types of impurities identified The choice of excipient and the respective level of impurities are critical factors influencing API stability Formulation of mannitols from different suppliers using direct compression
  • 18. Impurities Example: Reducing sugars in Parteck® M excipient batch to batch Webinar API stability in solid dose - How can excipients support you?18 Typical values of an impurity are never the same as the specification limits.
  • 19.
  • 20. Peroxides in ready-to-use ODT systems Composition of RTU ODT excipient systems:  A: Mannitol, croscarmellose sodium  B: Lactose, starch  C: Mannitol, crospovidone, povidone, polyvinyl acetate  D: Mannitol, xylitol, MCC, crospovidone, calcium dihydrogen phosphate dihydrate  E: Mannitol, xylitol, MCC, crospovidone, Mg Al Silicate  F: Mannitol, fructose, MCC, silicon dioxide, crospovidone  G: Mannitol, starch Oxidation Webinar API stability in solid dose - How can excipients support you?20 Look for low levels of peroxides to improve API stability
  • 21.
  • 22. Compression Force How can compression force affect API stability? Temperature rise Shear force breaks up large molecules Shear force breaks up coated API particles Webinar API stability in solid dose - How can excipients support you?22
  • 23. Compression Force Effect on coated API particles 23 Webinar API stability in solid dose - How can excipients support you? API F API API F API Stability Sustained release Taste Masking
  • 24. Compression Force Webinar API stability in solid dose - How can excipients support you?24 Old formulation Filler/binder Mannitol C Compression force 18 kN Tablet hardness 40 N DC Case Study: Enhanced stability of Vit. D3 by reduced compression force
  • 25. Compression Force DC Case Study: Enhanced stability of Vit. D3 by reduced compression force Webinar API stability in solid dose - How can excipients support you?25 Old formulation New formulation Filler/binder Mannitol C Mannitol B Compression force 18 kN 2 kN Tablet hardness 40 N 55 N Using the right excipient can help maximize hardness with minimizing compression force
  • 26. Compression Force Evaluation of different excipients for direct compression Webinar API stability in solid dose - How can excipients support you?26 Sorbitol and spray-dried mannitol deliver superior compressibility
  • 27. Compression Force Particle Engineering creates compressibility Webinar API stability in solid dose - How can excipients support you?27 Large surface areas show great compressibility
  • 28.
  • 29. What is most suitable for sensitive APIs: Wet granulation? Roller compaction? Webinar API stability in solid dose - How can excipients support you?29 Direct compression!
  • 30. Granulation Process Limitations in direct compression Webinar API stability in solid dose - How can excipients support you?30 1 2 3 Content Uniformity Compressibility Flow
  • 31. Granulation Process Statistical mixture vs ordered mixture Webinar API stability in solid dose - How can excipients support you?31 Common knowledge: Homogenous mixtures only possible for similar particle sizes
  • 32. Granulation Process Statistical mixture vs ordered mixture Webinar API stability in solid dose - How can excipients support you?32
  • 33. Spray-dried Mannitol A + 1% Ascorbic Acid < 10µm Spray-dried Mannitol B + 1% Ascorbic Acid < 10µm Granulation Process Statistical mixture vs ordered mixture Webinar API stability in solid dose - How can excipients support you?33 Large structured surface enables ordered mixtures by adsorption of the API
  • 34.
  • 35. Case study 1 Direct compression with low dose actives Webinar API stability in solid dose - How can excipients support you?35 Avicel is a registered trademark of FMC Corporation, Delaware, USA. Compritol is a registered trademark of Gattefossé SAS, Saint-Priest, France. A low dose water-sensitive active should be directly compressed
  • 36. Webinar API stability in solid dose - How can excipients support you?36 40.000 Tab/h 80.000 Tab/h Tablet weight 120.1 mg (rel.sd.: 0.6%) 118.8 (rel.sd.: 0.9%) Hardness 178 N (rel.sd. 4.1%) 173 N (rel.sd: 4.1%) Disintegration 3'25'' 3'22'' Structured surface enables perfect content uniformity; good flow leads to constant perfomance Case study 1 Direct compression with low dose actives
  • 37. Webinar API stability in solid dose - How can excipients support you?37 Case study 1 How can we explain that?
  • 38.
  • 39. Highlight traditionally difficult unstable API: Atorvastatin Atorvastatin is known to be:  Heat sensitive  Moisture sensitive  Oxidation sensitive  Light sensitive  Acid sensitive  Unstable in amorphous form Case study 2 API Stability 39 Webinar API stability in solid dose - How can excipients support you?
  • 40. Use Mannitol in direct compression together with alkalizer Case study 2 How to solve stability issues of Atorvastatin? 40 Webinar API stability in solid dose - How can excipients support you?  Heat sensitive  Moisture sensitive  Oxidation sensitive  Light sensitive  Acid sensitive  Unstable in amorphous form  Omit wet granulation  Direct compression  Low compression force  Keep out peroxides  Add alkalizer (Meglumine Parteck® MgDC Excipient, CaCO3)
  • 41. API stability in solid dose – How can excipients support you? Key takeaways Webinar API stability in solid dose - How can excipients support you?41
  • 42.
  • 43. Dr. Leo Ohrem hans-leonhard.ohrem@emdgroup.com The vibrant M is a trademark of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.